β-catenin 过表达可预测胶质瘤的疾病进展与不良预后：一项 Meta 分析
卞潇涵1 张小兵2 冯初狄1 董昌明2

1绍兴文理学院医学院，浙江省绍兴市，312000；

2绍兴市人民医院，浙江省绍兴市，312000；绍兴文理学院附属第一医院，浙江省绍兴市，312000；

摘要：背景：β-连环蛋白（β-catenin）在多种人类恶性肿瘤中呈高表达状态，但其与胶质瘤患者预后的关系尚存争议。方法：我们全面检索Medline（PubMed）、Embase及Web of Science数据库中已发表的文献，通过系统性 meta 分析探讨 β-catenin表达在胶质瘤中的预后价值。计算总生存期（OS）的合并风险比（HR）及 95% 置信区间（CI），用以分析β-catenin表达水平与胶质瘤患者预后之间的关联。结果：本研究最终纳入了8项研究，共计分析了871例患者的数据。分析结果显示，β-catenin过表达与胶质瘤患者的不良预后显著相关（总生存期：HR=1.67，95% CI：1.28–2.18；Z = 3.81；P < 0.0001）。进一步按不同病理类型进行亚组分析发现，β-catenin过表达与胶质母细胞瘤患者不良预后显著相关（总生存期：HR=1.85，95% CI：1.28–2.66；Z = 3.31；P = 0.001）。结论：β-catenin过表达与胶质瘤患者总生存期死亡风险的显著增加相关，或可作为潜在预后标志物以指导临床管理。

关键词：β-catenin；预后价值；胶质瘤；Meta分析

参考文献

[1]Siegel, R.L., K.D. Miller, and A. Jemal, Cancer statistics, 2020. CA Cancer J Clin, 2020. 70(1): p. 7-30.

[2]Mazor, T., et al., DNA Methylation and Somatic Mutations Converge on the Cell Cycle and Define Similar Evolutionary Histories in Brain Tumors. Cancer Cell, 2015. 28(3): p. 307-317.

[3]Nusse, R. and H. Clevers, Wnt/β-Catenin Signaling, Disease, and Emerging Therapeutic Modalities. Cell, 2017. 169(6): p. 985-999.

[4]Anastas, J.N. and R.T. Moon, WNT signalling pathways as therapeutic targets in cancer. Nat Rev Cancer, 2013. 13(1): p. 11-26.

[5]Shi, Z., et al., Nuclear translocation of β-catenin is essential for glioma cell survival. J Neuroimmune Pharmacol, 2012. 7(4): p. 892-903.

[6]Stang, A., Critical evaluation of the Newcastle-Ottawa scale for the assessment of the quality of nonrandomized studies in meta-analyses. Eur J Epidemiol, 2010. 25(9): p. 603-5.

[7]Liu, H.W., et al., The Disruption of the β-Catenin/TCF-1/STAT3 Signaling Axis by 4-Acetylantroquinonol B Inhibits the Tumorigenesis and Cancer Stem-Cell-Like Properties of Glioblastoma Cells, In Vitro and In Vivo. Cancers (Basel), 2018. 10(12).

[8]Wu, W., et al., The expressions of Wnt/β-catenin pathway-related components in brainstem gliomas. Can J Neurol Sci, 2013. 40(3): p. 355-60.

[9]Yang, W., et al., Nuclear PKM2 regulates β-catenin transactivation upon EGFR activation. Nature, 2011. 480(7375): p. 118-22.

[10]Ellison, D.W., et al., Definition of disease-risk stratification groups in childhood medulloblastoma using combined clinical, pathologic, and molecular variables. J Clin Oncol, 2011. 29(11): p. 1400-7.

[11]Tierney, J.F., et al., Practical methods for incorporating summary time-to-event data into meta-analysis. Trials, 2007. 8: p. 16.

[12]Li, J.Z., et al., [Clinicopathologic significance of β-catenin protein and loss of heterozygosity on 10q in medulloblastoma]. Zhonghua Bing Li Xue Za Zhi, 2012. 41(12): p. 823-7.

[13]Liu, C., et al., Wnt/beta-Catenin pathway in human glioma: expression pattern and clinical/prognostic correlations. Clin Exp Med, 2011. 11(2): p. 105-12.

[14]Zhang, L.Y., et al., Reduced beta-catenin expression is associated with good prognosis in Astrocytoma. Pathol Oncol Res, 2010. 16(2): p. 253-7.

[15]Kim, S.A., et al., Promoter methylation of WNT inhibitory factor-1 and expression pattern of WNT/β-catenin pathway in human astrocytoma: pathologic and prognostic correlations. Mod Pathol, 2013. 26(5): p. 626-39.

[16]Schüle, R., et al., Potential canonical wnt pathway activation in high-grade astrocytomas. ScientificWorldJournal, 2012. 2012: p. 697313.

[17]Wang, C., et al., The positive correlation between DJ-1 and β-catenin expression shows prognostic value for patients with glioma. Neuropathology, 2013. 33(6): p. 628-36.

[18]Patil, S.S., et al., Insulin-like growth factor binding protein-2 regulates β-catenin signaling pathway in glioma cells and contributes to poor patient prognosis. Neuro Oncol, 2016. 18(11): p. 1487-1497.

[19]Chang, L., et al., Expression and prognostic value of SFRP1 and β-catenin in patients with glioblastoma. Oncol Lett, 2016. 11(1): p. 69-74.

[20]Ellison, D.W., et al., beta-Catenin status predicts a favorable outcome in childhood medulloblastoma: the United Kingdom Children's Cancer Study Group Brain Tumour Committee. J Clin Oncol, 2005. 23(31): p. 7951-7.

[21]Ikeda, S., et al., Axin, a negative regulator of the Wnt signaling pathway, forms a complex with GSK-3beta and beta-catenin and promotes GSK-3beta-dependent phosphorylation of beta-catenin. Embo j, 1998. 17(5): p. 1371-84.

[22]Behrens, J., et al., Functional interaction of beta-catenin with the transcription factor LEF-1. Nature, 1996. 382(6592): p. 638-42.